Description

Epaidra (insulin glulisine) SoloStar Solution for Injections 100 IU/ml. 3 ml. Cartridge №5 + Syringe

Ingredients:

Each ml contains 100 IU of insulin glulisine. Other ingredients include metacresol, glycerol, zinc oxide, hydrochloric acid, and sodium hydroxide.

Dosage:

The dosage of Epaidra (insulin glulisine) should be individualized based on the patient’s needs. It is typically injected subcutaneously before meals. Consult a healthcare provider for the correct dosage.

Indications:

Epaidra (insulin glulisine) is indicated for the treatment of diabetes mellitus in adults and children. It helps control blood sugar levels to prevent complications of diabetes.

Contraindications:

Do not use Epaidra (insulin glulisine) if you are allergic to insulin glulisine or any of the ingredients in the product. It is not recommended for use during episodes of hypoglycemia.

Directions:

Before use, check the solution for any particles or discoloration. Inject the prescribed dose subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy.

Scientific Evidence:

Studies have shown that insulin glulisine, the active ingredient in Epaidra, has a rapid onset of action and shorter duration compared to regular human insulin. This rapid action helps mimic the body’s natural insulin response after meals, leading to better postprandial glucose control.

Clinical trials have demonstrated the efficacy of Epaidra in improving glycemic control in patients with diabetes. The fast-acting nature of insulin glulisine makes it a valuable option for managing blood sugar levels in both type 1 and type 2 diabetes.